Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eisai Co., Ltd.
Age
20–79
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
lnclusion Criteria:
Male and female patients 20 to less than 80 years of age at the time of informed consent
Patients histologically or cytologically diagnosed to have peripheral T -cell lymphoma
Patients with a history of chemotherapy (including PUVA and retinoid) that resulted in relapse, recurrence and treatment resistance (just for the administration of E7777 alone)
Patients subject to CHOP therapy and without a history of prior treatment with anthracycline or anthraquinone anticancer drugs (just for the administration of E7777 in combination with CHOP therapy)
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
No carry-over of beneficial or adverse effects of the prior treatment that may affect the safety evaluation of the investigational drug (excluding Grade 1 neuropathy and alopecia)
You may not be if
Brain metastasis with clinical symptoms which requires treatment
